Search

Your search keyword '"Wedemeyer, Heiner"' showing total 3,190 results

Search Constraints

Start Over You searched for: Author "Wedemeyer, Heiner" Remove constraint Author: "Wedemeyer, Heiner"
3,190 results on '"Wedemeyer, Heiner"'

Search Results

12. Detection of polyreactive immunoglobulin G facilitates diagnosis in children with autoimmune hepatitis

13. Correction to: Diagnosis and Management of Hepatitis Delta Virus Infection

14. Diagnosis and Management of Hepatitis Delta Virus Infection

16. Real-world effectiveness and safety of bulevirtide monotherapy for up to 96 weeks in patients with HDV-related cirrhosis

18. Novel translational mouse models of metabolic dysfunction-associated steatotic liver disease comparable to human MASLD with severe obesity

21. HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx

22. Bulevirtide monotherapy in patients with chronic HDV: Efficacy and safety results through week 96 from a phase III randomized trial

26. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta

27. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure

31. Weissbuch Gastroenterologie 2023/24

35. BISCIT: Biliary interventions in critically ill patients with secondary sclerosing cholangitis—a study protocol for a multicenter, randomized, controlled parallel group trial

37. HBV shows different levels of adaptation to HLA class I-associated selection pressure correlating with markers of replication

38. HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy

42. Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022

43. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

44. A global research priority agenda to advance public health responses to fatty liver disease

45. No virologic resistance to bulevirtide monotherapy detected in patients through 24 weeks treatment in phase II and III clinical trials for chronic hepatitis delta

46. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study

Catalog

Books, media, physical & digital resources